EQUITY ALERT: Rosen Law Firm P.A. Reminds AcelRx Pharmaceuticals, Inc. Investors of Important Class Action Deadline - ACRX

NEW YORK, Oct. 22, 2014 (GLOBE NEWSWIRE) -- Rosen Law Firm, P.A. reminds purchasers of the common stock and call options and sellers of put options of AcelRx Pharmaceuticals, Inc. ACRX during the period from December 2, 2013 through September 25, 2014, of the important December 1, 2014 lead plaintiff deadline in the class action.

To join the AcelRx class action, visit the firm's website at http://rosenlegal.com/cases-388.html, or call Phillip Kim or Kevin Chan toll-free at 866-767-3653; you may also email pkim@rosenlegal.com or kchan@rosenlegal.com for information on the class action. The lawsuit filed by the firm is pending in the U.S. District Court for the Northern District of California.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY CHOOSE TO DO NOTHING AT THIS POINT AND REMAIN AN ABSENT CLASS MEMBER.

The lawsuit alleges that defendants made false and/or misleading statements concerning their Zalviso system pain management product. In particular, the complaint alleges that: (1) the Instructions for Use (IFU) for Zalviso were not designed to adequately address the risk of the accidental misplacement of tablets; (2) AcelRx had not submitted to the FDA sufficient data to support the shelf life of Zalviso; and (3) as a result of the foregoing, AcelRx's statements concerning Zalviso, including the drug's regulatory approval and financial prospects, were materially false and misleading.

On July 25, 2014 AcelRx announced that it had received a Complete Response Letter ("CRL") from the FDA regarding its New Drug Application for Zalviso. The FDA requested additional information on the Zalviso System to ensure proper use of the device, including changes to the Instructions for Use for the device and additional data to support the shelf life of the product. This news caused shares of AcelRx to decline $4.44/share, or 40%, the next trading day.

Then when AcelRx disclosed on September 26, 2014 that the resubmission process for its Zalviso NDA would not be complete until the first quarter of 2015, and that the planned resubmission will have a review period of six months, shares of AcelRx declined $1.31/share, or over 19%, causing investors substantial losses.

If you wish to serve as lead plaintiff, you must move the Court no later than December 1, 2014. If you wish to join the litigation and recover your losses go to http://rosenlegal.com/cases-388.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim or Kevin Chan of The Rosen Law Firm, toll-free, at 866-767-3653, or via e-mail at pkim@rosenlegal.com or kchan@rosenlegal.com.

The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.